



January 3, 2017

## **Ardelyx Announces Presentation at J.P. Morgan 35th Annual Healthcare Conference**

FREMONT, Calif., Jan. 3, 2017 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage company focused on enhancing the treatment of patients with gastrointestinal and cardiorenal diseases, today announced that Mike Raab, chief executive officer of Ardelyx, will present a company overview at the J.P. Morgan 35<sup>th</sup> Annual Healthcare Conference on Tuesday, January 10, 2017 at 3:30 p.m. PT. The conference is taking place January 9-12, 2017 at the Westin St. Francis in San Francisco.



To access the live webcast of Ardelyx's presentation please visit the Events & Presentations page within the Investor page of the Ardelyx website at [ir.ardelyx.com](http://ir.ardelyx.com). Replays of the webcast will be available on the Ardelyx website for 90 days following the conference.

### **About Ardelyx, Inc.**

Ardelyx is focused on enhancing the care and well-being of underserved patients with gastrointestinal (GI) and cardiorenal diseases by using the gut as the gateway to developing high-quality therapeutics. The company has pioneered the development of small molecule therapeutics that act predominantly in the GI tract, thereby avoiding potential negative side effects on the rest of the body. Ardelyx's platform integrates technology that emulates the human GI tract with its gut-restricted chemistry capabilities allowing for the development of optimized small molecules in a rapid and cost-efficient manner. Using its platform, Ardelyx has discovered and developed multiple portfolios of unique, gut-targeted therapeutics. The company's GI portfolio is led by tenapanor, which is in Phase 3 development for the treatment of irritable bowel syndrome with constipation (IBS-C), and RDX8940, a unique TGR5 agonist that is approaching Phase 1 development. Ardelyx's cardiorenal portfolio includes the Phase 3 development of tenapanor for the treatment of hyperphosphatemia in patients with end-stage renal disease (ESRD) on dialysis, and RDX7675, in Phase 3 development for the treatment of patients with hyperkalemia, or high potassium, a problem prevalent in people with kidney and/or heart disease. The company is also advancing several research programs in its GI and cardiorenal portfolios. For more information, please visit [www.ardelyx.com](http://www.ardelyx.com).

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/ardelyx-announces-presentation-at-jp-morgan-35th-annual-healthcare-conference-300384445.html>

SOURCE Ardelyx

News Provided by Acquire Media